WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that it has been named one of The Boston
Globe's Top Places to Work. The Company has received this recognition
for the third consecutive year and in four of the last five years.
"We are extremely pleased that ImmunoGen has once again been recognized
as one of The Boston Globe's Top Places to Work," commented Daniel
Junius, President and CEO. "It is the expertise and dedication of our
entire organization that has brought ImmunoGen to where we are today: a
company with a validated technology, a highly promising lead product
program moving into a study we intend to use for registration purposes,
a rich pipeline and partnerships with a number of leading healthcare
companies. We are proud that we continue to attract and retain employees
who are committed to our mission of making a difference in the lives of
patients with cancer."
The Boston Globe's 2015 Top Places to Work recognizes the most
admired workplaces in the state. The rankings in Top Places to Work are
based on confidential survey information collected by WorkplaceDynamics,
an independent company specializing in employee engagement and
retention, from nearly 77,000 individuals at a wide array of
Massachusetts organizations. The survey measures employee opinions about
their company's direction, execution, connection, management, work, pay
and benefits, and engagement. The winners share a few key traits,
including offering progressive benefits, giving their employees a voice,
and encouraging them to have some fun while they're at it.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted anticancer therapeutics using its proprietary ADC technology.
The Company's lead product candidate, mirvetuximab soravtansine, is a
potential treatment for FRα-positive ovarian cancer and other solid
tumors. A number of major healthcare companies have licensed limited
rights to use ImmunoGen's ADC technology to develop anticancer
therapies; it is used in Roche's marketed product, Kadcyla®.
More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including mirvetuximab soravtansine (IMGN853), including risks related
to clinical studies and regulatory processes, their timings and results.
A review of these risks can be found in ImmunoGen's Annual Report on
Form 10-K for the fiscal year ended June 30, 2015 and other reports
filed with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151113005123/en/
Carol Hausner, 781-895-0600
Source: ImmunoGen, Inc.
News Provided by Acquire Media